Attention-deficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks?

@article{Hammerness2015AttentiondeficithyperactivityDT,
  title={Attention-deficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks?},
  author={P. Hammerness and Chris Karampahtsis and R. Babalola and M. Alexander},
  journal={Expert Opinion on Drug Safety},
  year={2015},
  volume={14},
  pages={543 - 551}
}
Introduction: This drug safety review provides an update on the long-term cardiovascular risks of therapeutic stimulant class medication for children and adults with attention-deficit/hyperactivity disorder (ADHD). Areas covered: Relevant literature on the long-term (defined as ≥ 12 months) cardiovascular effects of stimulant class medications for ADHD was sought using PubMed searches for clinical literature, epidemiological reports, as well as reviews of post-marketing data and clinical… Expand
14 Citations
Pediatric pharmacoepidemiology - safety and effectiveness of medicines for ADHD
  • 14
Challenges and Promises of Pediatric Psychopharmacology.
  • 14
Adult ADHD and Comorbid Somatic Disease: A Systematic Literature Review
  • 81
  • PDF
Use of drugs for ADHD among adults—a multinational study among 15.8 million adults in the Nordic countries
  • 22
  • PDF
Pediatric Psychopharmacology: a Primer for the Treatment of Common Mental Health Conditions
  • M. Gleason
  • Medicine
  • Current Treatment Options in Pediatrics
  • 2017
...
1
2
...

References

SHOWING 1-10 OF 93 REFERENCES
Cardiovascular Effects of Medications for the Treatment of Attention-Deficit Hyperactivity Disorder
  • 31
ADHD medications and risk of serious cardiovascular events in young and middle-aged adults.
  • 202
  • PDF
Cardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: a nationwide prospective cohort study.
  • 58
  • PDF
Two-year outcome of treatment with central stimulant medication in adult attention-deficit/hyperactivity disorder: a prospective study.
  • 53
Relative cardiovascular safety of psychostimulants used to treat attention-deficit hyperactivity disorder.
  • D. Safer
  • Psychology, Medicine
  • Journal of child and adolescent psychopharmacology
  • 1992
  • 41
...
1
2
3
4
5
...